GEP-NETGastroenteropancreatic Neuroendocrine tumor
References in periodicals archive ?
This is the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NETs, added the company.
GEP-NETs can be present in the pancreas and in different parts of the gastrointestinal tract.
Complete or partial tumour shrinkage was reported in 16% of a subset of 360 patients with GEP-NETs who were evaluated for response by the US FDA.